Bjorn Henning Gronberg, MD, PhD, on SCLC: Adjuvant Immunotherapy After CRT
2025 ASCO Annual Meeting
Bjorn Henning Gronberg, MD, PhD, of Norwegian University of Science and Technology (NTNU) and St. Olavs Hospital, presents phase II findings on the efficacy of atezolizumab after chemoradiotherapy (CRT) in limited-stage small cell lung cancer (SCLC) (LBA8005).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
We enrolled 216 patients at 37 hospitals in six countries of Europe, and out of those, 170 patients were randomized to receive either one year of atezolizumab or observation. The main endpoint was overall survival, and unfortunately we did not see any signal of an effect, neither for progression-free survival, so this is clearly a negative trial. Looking at subgroups, we do see that there are some differences in the effect depending on gender. Among women, patients on the observation arm lived much longer than expected, while among men there appears to be a signal of an effect. We also see that the choice of platinum had some influence on the survival curves. We see that among patients who received carboplatin, maybe there's a signal of an effect quite similar to what we actually saw also in the ADRIATIC trial. Median treatment time was 8 courses. Overall, there were more side effects in the experimental arm, but maybe not any single adverse event—it's more the totality. On the other hand, patients on the observation arm didn't meet the investigators as often as the patients who came regularly for infusions of atezolizumab. I think overall this study shows that the concept of adding checkpoint inhibitors after chemoradiated therapy in limited-stage small cell lung cancer is tolerable, even if this intervention did not prolong PFS or overall survival.
The ASCO Post Staff
Hope S. Rugo, MD, FASCO, of City of Hope, and Rebecca Alexandra Dent, MD, FASCO, of National Cancer Centre Singapore, review the results of a biomarker analysis of the DESTINY-Breast06 trial, which evaluated trastuzumab deruxtecan after endocrine therapy in patients with metastatic breast cancer (Abstract 1013). They also discuss findings from the SERENA-6 and EMBER-3 trials, also presented at ASCO 2025, and what all this new data means for the sequencing of endocrine therapy in patients with breast cancer.
The ASCO Post Staff
Mafalda Oliveira, MD, PhD, of Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, discusses findings on the incidence and management of hyperglycemia in a subset of patients with prediabetes and/or obesity included in the phase I trial of inavolisib alone and in combination with endocrine therapy with or without palbociclib for PIK3CA-mutated, hormone receptor–positive, HER2-negative locally advanced/metastatic breast cancer (Abstract 1004).
The ASCO Post Staff
Sameek Roychowdhury, MD, PhD, of the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at The Ohio State University Wexner Medical Center, discusses a recently opened telemedicine clinical trial of pemigatinib in patients with advanced or metastatic FGFR-mutated pancreatic cancer, and the germination of a new initiative, TNT Cancer, which focuses on leveraging telemedicine to bring trials nationwide.
The ASCO Post Staff
Nicholas C. Turner, MD, PhD, of the Royal Marsden Hospital, presents final overall survival data from the INAVO120 trial of inavolisib/placebo plus palbociclib and fulvestrant in patients with PIK3CA-mutated, HR-positive, HER2-negative, endocrine-resistant advanced breast cancer (Abstract 1003).
The ASCO Post Staff
Manmeet Singh Ahluwalia, MD, MBA, FASCO, of Miami Cancer Institute, Baptist Health South Florida, discusses the ongoing LIBERATE trial, which is evaluating safety and technical efficacy of transcranial MR-guided microbubble-enhanced transcranial focused ultrasound for increasing blood circulating tumor and cell-free DNA levels in adults with glioblastoma (Abstract TPS2094).
